Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.
Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.
Recently, in response to the global challenge of COVID-19, Kinarus has initiated clinical evaluation of its combination therapy to treat patients suffering from SARS-CoV-2 infection. Kinarus has discovered that KIN001 has anti-viral activity against SARS-CoV-2, including against its variants of concern. KIN001 also possesses anti-inflammatory and anti-fibrotic activity.
Hochbergerstrasse 60C, 4057 Basel – Switzerland
|Date||Trading entity / Person||Association||Trade type||Volume|
|31.10.23||None||Executive member||Sell||CHF 4,248.75|
|07.09.23||None||Executive member||Sell||CHF 11,713.02|
|23.06.23||None||Executive member||Sell||CHF 45,028.85|
|13.06.23||None||Executive member||Sell||CHF 38,761.94|
|05.06.23||None||Executive member||Sell||CHF 1,417,143.65|
|02.06.22||None||Executive member||Buy||CHF 7,441,035.53|
|02.06.22||None||Non-Executive member||Buy||CHF 2,483,942.78|
|02.06.22||None||Executive member||Buy||CHF 922,192.69|
|02.06.22||None||Executive member||Buy||CHF 399,716.30|
|02.06.22||None||Non-Executive member||Buy||CHF 337,068.73|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.